Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

鈥� An ASCO Reading Room selection

March 11, 2024

Luisa M. Cardenas, MD, Sunita Ghosh, PhD, Antonio Finelli, MD, Lori Wood, MD, Christian Kollmannsberger, MD, Naveen Basappa, MD, Jeffrey Graham, MD, Daniel Heng, MD, Georg Bjarnason, MD, Denis Souli猫res, MD, Dominick Boss茅, MD, Vincent Castonguay, MD, Ramy Saleh, MD, Simon Tanguay, MD, Bimal Bhindi, MD, Rodney H. Breau, MD, Frederic Pouliot, MD, and Aly-Khan A. Lalani, MD

JCO Global Oncology

This Reading Room is a collaboration between 番茄社区庐 and:

Below is the abstract of the article.

Read the full article PDF by clicking here

or on the link below.

Purpose

Standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have greatly evolved. However, the availability of emerging options in global health care systems can vary. We sought to describe the integration and usage of systemic therapies for mRCC in Canada since 2011.

Methods

We included patients with mRCC enrolled in the Canadian Kidney Cancer Information System, a prospective cohort of patients from 14 Canadian academic centers, who received systemic therapy from January 1, 2011, to December 31, 2021. Patients were stratified by treatment era (cohort 1: 2011-2015, cohort 2: 2016-2021). Stacked bar charts were used to present treatment proportions; Sankey diagrams were used to show the evolution of treatment sequencing between the two cohorts.

Results

Four thousand one hundred seven patients were diagnosed with mRCC, of whom 2,752 (67%) received systemic therapy. Among these patients, mean age was 64 years, 74% were male, 75% had clear cell histology, and International Metastatic RCC Database Consortium risk classification was favorable, intermediate, and poor in 16%, 56%, and 28%, respectively. Utilization of immune checkpoint inhibition (ICI)–based treatments has increased in Canada and reflects global and local patterns of approval and adoption. The use of therapies after doublet ICI has mostly shifted toward vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) that were previously used in first line with subsequent treatments reflecting approved and available agents after previous VEGF-TKI. Clinical trial participation among patients who received systemic therapy was 18% in first, 21% in second, and 24% in third line.

Conclusion

In Canada's publicly funded health care system, availability of standard mRCC therapies broadly reflects access from government-funded clinical trials and compassionate access program sources. In an evolving therapeutic landscape, ongoing advocacy is required to continue to facilitate patient access to efficacious therapies.

Read an interview about the study here.

Read the full article

Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

Primary Source

JCO Global Oncology

Source Reference:

番茄社区